IRIS
CONTEDUCA, VINCENZA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.077
EU - Europa 2.903
AS - Asia 2.568
SA - Sud America 1.099
Continente sconosciuto - Info sul continente non disponibili 599
AF - Africa 68
OC - Oceania 4
Totale 11.318
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.921
IE - Irlanda 1.086
SG - Singapore 1.011
BR - Brasile 897
RU - Federazione Russa 701
HK - Hong Kong 437
VN - Vietnam 435
CN - Cina 341
IT - Italia 285
SE - Svezia 273
FR - Francia 172
DE - Germania 111
BD - Bangladesh 75
AR - Argentina 73
CA - Canada 67
GB - Regno Unito 63
IN - India 49
FI - Finlandia 47
MX - Messico 44
ID - Indonesia 39
UA - Ucraina 38
EC - Ecuador 35
CO - Colombia 30
AE - Emirati Arabi Uniti 25
NL - Olanda 25
IQ - Iraq 24
TR - Turchia 23
ZA - Sudafrica 20
ES - Italia 18
PL - Polonia 18
AT - Austria 15
PY - Paraguay 15
VE - Venezuela 14
JP - Giappone 12
SA - Arabia Saudita 12
CL - Cile 11
PE - Perù 11
UZ - Uzbekistan 11
MA - Marocco 10
PK - Pakistan 10
UY - Uruguay 10
DO - Repubblica Dominicana 9
EG - Egitto 8
JM - Giamaica 8
NP - Nepal 8
BE - Belgio 7
PH - Filippine 7
NO - Norvegia 6
CR - Costa Rica 5
DZ - Algeria 5
HN - Honduras 5
LT - Lituania 5
OM - Oman 5
SK - Slovacchia (Repubblica Slovacca) 5
SY - Repubblica araba siriana 5
AZ - Azerbaigian 4
ET - Etiopia 4
IL - Israele 4
KE - Kenya 4
LB - Libano 4
RO - Romania 4
TN - Tunisia 4
TT - Trinidad e Tobago 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AU - Australia 3
GR - Grecia 3
JO - Giordania 3
MD - Moldavia 3
MY - Malesia 3
NI - Nicaragua 3
TW - Taiwan 3
AL - Albania 2
BB - Barbados 2
BH - Bahrain 2
BN - Brunei Darussalam 2
BO - Bolivia 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
CZ - Repubblica Ceca 2
GE - Georgia 2
GT - Guatemala 2
HR - Croazia 2
KW - Kuwait 2
KZ - Kazakistan 2
LY - Libia 2
MK - Macedonia 2
PR - Porto Rico 2
SC - Seychelles 2
SN - Senegal 2
SV - El Salvador 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BZ - Belize 1
CH - Svizzera 1
CY - Cipro 1
DK - Danimarca 1
EE - Estonia 1
GA - Gabon 1
GH - Ghana 1
GP - Guadalupe 1
Totale 10.707
Salva come PNG Salva come JPEG
Città #
Dublin 1.083
San Jose 1.008
Hong Kong 435
Singapore 414
Ashburn 368
Columbus 268
Nyköping 208
Santa Clara 179
Council Bluffs 170
Ho Chi Minh City 165
Chandler 146
Lauterbourg 137
Princeton 129
Wilmington 128
Dallas 127
Hanoi 84
São Paulo 82
Beijing 73
The Dalles 58
Munich 51
New York 41
Moscow 35
Los Angeles 32
Helsinki 26
Des Moines 25
North Bergen 25
Belo Horizonte 23
Chicago 21
Da Nang 21
Rio de Janeiro 21
Nuremberg 20
Phoenix 20
Rome 19
Brasília 18
Jacksonville 18
London 18
Brooklyn 17
Quito 17
Shanghai 17
Atlanta 16
Milan 16
Turku 16
Warsaw 15
Hudson 14
Mexico City 14
Curitiba 13
Guarulhos 13
San Francisco 13
Thái Bình 13
Bari 12
Buenos Aires 12
Frankfurt am Main 12
Porto Alegre 12
Guangzhou 11
Hillsboro 11
Martina Franca 11
Nanjing 11
Orem 11
Salvador 11
Toronto 11
Can Tho 10
Haiphong 10
Ninh Bình 10
Nocera Inferiore 10
Seattle 10
Tashkent 10
Biên Hòa 9
Buffalo 9
Campinas 9
Chennai 9
Dhaka 9
Johannesburg 9
Norwalk 9
Ribeirão Preto 9
Tokyo 9
Trento 9
Boston 8
Dearborn 8
Goiânia 8
Madrid 8
Montevideo 8
Montreal 8
Stockholm 8
Thái Nguyên 8
Wuhan 8
Amsterdam 7
Ankara 7
Caxias do Sul 7
Formosa 7
Fortaleza 7
Hortolândia 7
Hải Dương 7
Itaquaquecetuba 7
Lima 7
Lấp Vò 7
Mumbai 7
Potenza 7
Brussels 6
Canoas 6
Garden City 6
Totale 6.339
Salva come PNG Salva come JPEG
Nome #
Pathophysiology of HCV-Related cryoglobulinemic vasculitis: molecular, immunological and clinical analysis 191
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 128
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis 114
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. 114
Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer 110
Adenosine A3 receptor antagonists as anti-tumor treatment in human prostate cancer: an in vitro study 109
Circulating Tumor DNA: A New Research Frontier in Urological Oncology from Localized to Metastatic Disease 104
Axitinib after Sunitinib in metastatic renal cancer: Preliminary results from Italian "Real-World" SAX Study 104
T cell receptor variable β gene repertoire in liver and peripheral blood lymphocytes of chronically hepatitis C virus-infected patients with and without mixed cryoglobulinaemia. 101
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation 99
Androgen receptor signaling pathways as a target for breast cancer treatment 98
Anogenital lichen sclerosus et atrophicus lesions in a case series of cancer patients on immunotherapy. 98
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience 98
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients 96
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study 95
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. 90
Association among metabolic syndrome, inflammation, and survival in prostate cancer 90
Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage 90
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. 89
B-cell frequency in hepatitis C virus-related mixed cryoglobulinemia 89
Androgen receptor, PARP signaling, and tumor microenvironment: the ‘perfect triad’ in prostate cancer? 89
Clinical features of neuroendocrine prostate cancer 88
Serum Mass Spectrometry Proteomics and Protein Set Identification in Response to FOLFOX-4 in Drug-Resistant Ovarian Carcinoma 87
AR copy number and AR signaling-directed therapies in castration-resistant prostate cancer 87
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer 86
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer 85
Epigenetics in prostate cancer: clinical implications 84
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide 84
Immunogenomic profiles associated with response to life-prolonging agents in prostate cancer 83
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. 82
Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers 81
H. pylori infection and gastric cancer: State of the art (Review) 81
Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test 81
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer 81
The prostatic inflammation score and risk of biochemical recurrence following radical prostatectomy 79
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 79
Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents 79
Biological Evolution of Castration-resistant Prostate Cancer 79
Barrett's esophagus and esophageal cancer: An overview 79
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. 79
Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer 78
Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer 78
Barrett's esophagus and esophageal cancer: An overview 78
Interleukin 28B Gene Polymorphisms in Hepatitis C Virus-related Cryoglobulinemic Vasculitis 77
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA. 77
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. 77
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma. 77
Plasma AR and abiraterone-resistant prostate cancer 77
New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer. 76
Metabolic syndrome as a peculiar target for management of prostate cancer patients 76
Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone 75
Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer 75
Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone 75
Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network 74
Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma. 74
Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis 74
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care 73
Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide 73
Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. 72
Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724–31 72
TRAP1 modulates mitochondrial biogenesis via PGC-1α/TFAM signalling pathway in colorectal cancer cells 71
Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer 71
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer 70
BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy 70
Personalized medicine for metastatic prostate cancer: The paradigm of PARP inhibitors 68
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 68
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide 68
Impact of cryoglobulinemic syndrome on the outcome of chronic hepatitis C virus infection: A 15-year prospective study 68
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients. 68
Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis 66
The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment. 66
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 66
Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview 66
Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis 66
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis 65
High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer 65
PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer 65
Circulating tumor cells: Utopia or reality? 65
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives. 64
The emerging role of anti-angiogenic therapy in ovarian cancer (review) 63
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis 63
Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: A long-term study 63
Validation of a Combined Prognostic Score Using Plasma Tumor DNA and Clinical Features in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Taxanes 63
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer 62
The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer 61
Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis 61
Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. 61
The potential use of urine cell free DNA as a marker for cancer 61
The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversy 61
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone 61
Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide 60
Hepatitis C virus infection and mixed cryoglobulinemia 60
Cell-free DNA as a diagnostic marker for cancer: Current insights 60
Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone 60
Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial 59
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 59
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: Results of the Italian Named Patient Programme 59
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 58
Pharmacological treatment landscape of non-metastatic hormone-sensitive prostate cancer: A narrative review on behalf of the meet-URO Group 58
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study 58
Totale 7.815
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82.851
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 82.851
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022847 0 0 0 1 371 15 25 50 102 104 17 162
2022/20231.723 186 31 86 25 47 109 3 71 1.117 15 19 14
2023/2024222 11 19 11 19 26 77 1 21 8 7 1 21
2024/20252.162 103 68 11 30 61 257 223 100 591 206 247 265
2025/20264.690 245 458 619 1.028 142 121 778 441 372 286 133 67
2026/20271.526 147 408 334 637 0 0 0 0 0 0 0 0
Totale 11.318